237 related articles for article (PubMed ID: 24089559)
41. Cyclophillin A deficiency accelerates RML-induced prion disease.
Bouybayoune I; Comerio L; Pasetto L; Bertani I; Bonetto V; Chiesa R
Neurobiol Dis; 2019 Oct; 130():104498. PubMed ID: 31181281
[TBL] [Abstract][Full Text] [Related]
42. Mutant PrPSc conformers induced by a synthetic peptide and several prion strains.
Tremblay P; Ball HL; Kaneko K; Groth D; Hegde RS; Cohen FE; DeArmond SJ; Prusiner SB; Safar JG
J Virol; 2004 Feb; 78(4):2088-99. PubMed ID: 14747574
[TBL] [Abstract][Full Text] [Related]
43. Chemically induced accumulation of GAGs delays PrP(Sc) clearance but prolongs prion disease incubation time.
Mayer-Sonnenfeld T; Avrahami D; Friedman-Levi Y; Gabizon R
Cell Mol Neurobiol; 2008 Nov; 28(7):1005-15. PubMed ID: 18350378
[TBL] [Abstract][Full Text] [Related]
44. Induced neuroprotection independently from PrPSc accumulation in a mouse model for prion disease treated with simvastatin.
Haviv Y; Avrahami D; Ovadia H; Ben-Hur T; Gabizon R; Sharon R
Arch Neurol; 2008 Jun; 65(6):762-75. PubMed ID: 18541796
[TBL] [Abstract][Full Text] [Related]
45. Effect of Microglial Inflammation in Prion Disease.
Ano Y; Sakudo A; Onodera T
Curr Issues Mol Biol; 2020; 36():1-12. PubMed ID: 31486773
[TBL] [Abstract][Full Text] [Related]
46. The Effects of Divalent Cation-Chelated Prion Fibrils on the Immune Response of EOC 13.31 Microglia Cells.
Jen HI; Lin ZY; Guo JX; Lee CI
Cells; 2020 Oct; 9(10):. PubMed ID: 33066249
[TBL] [Abstract][Full Text] [Related]
47. Treatment of SMB-S15 Cells with Resveratrol Efficiently Removes the PrP(Sc) Accumulation In Vitro and Prion Infectivity In Vivo.
Wang J; Zhang BY; Zhang J; Xiao K; Chen LN; Wang H; Sun J; Shi Q; Dong XP
Mol Neurobiol; 2016 Oct; 53(8):5367-76. PubMed ID: 26440667
[TBL] [Abstract][Full Text] [Related]
48. Polo-like kinase 3 (PLK3) mediates the clearance of the accumulated PrP mutants transiently expressed in cultured cells and pathogenic PrP(Sc) in prion infected cell line via protein interaction.
Wang H; Tian C; Fan XY; Chen LN; Lv Y; Sun J; Zhao YJ; Zhang LB; Wang J; Shi Q; Gao C; Chen C; Shao QX; Dong XP
Int J Biochem Cell Biol; 2015 May; 62():24-35. PubMed ID: 25724737
[TBL] [Abstract][Full Text] [Related]
49. In Situ Temporospatial Characterization of the Glial Response to Prion Infection.
Michael AV; Greenlee JJ; Harm TA; Moore SJ; Zhang M; Lind MS; Greenlee MHW; Smith JD
Vet Pathol; 2020 Jan; 57(1):90-107. PubMed ID: 31331254
[TBL] [Abstract][Full Text] [Related]
50. Cellular pathogenesis in prion diseases.
Crozet C; Beranger F; Lehmann S
Vet Res; 2008; 39(4):44. PubMed ID: 18413130
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of prion deposits and microglial activation in scrapie-infected mice using molecular imaging probes.
Song PJ; Barc C; Arlicot N; Guilloteau D; Bernard S; Sarradin P; Chalon S; Garreau L; Kung HF; Lantier F; Vergote J
Mol Imaging Biol; 2010 Dec; 12(6):576-82. PubMed ID: 20376566
[TBL] [Abstract][Full Text] [Related]
52. A versatile prion replication assay in organotypic brain slices.
Falsig J; Julius C; Margalith I; Schwarz P; Heppner FL; Aguzzi A
Nat Neurosci; 2008 Jan; 11(1):109-17. PubMed ID: 18066056
[TBL] [Abstract][Full Text] [Related]
53. Small-ruminant lentivirus enhances PrPSc accumulation in cultured sheep microglial cells.
Stanton JB; Knowles DP; O'Rourke KI; Herrmann-Hoesing LM; Mathison BA; Baszler TV
J Virol; 2008 Oct; 82(20):9839-47. PubMed ID: 18684809
[TBL] [Abstract][Full Text] [Related]
54. TSE strain differentiation in mice by immunohistochemical PrP(Sc) profiles and triplex Western blot.
van Keulen LJ; Langeveld JP; Dolstra CH; Jacobs J; Bossers A; van Zijderveld FG
Neuropathol Appl Neurobiol; 2015 Oct; 41(6):756-79. PubMed ID: 25201447
[TBL] [Abstract][Full Text] [Related]
55. MCP-1 and murine prion disease: separation of early behavioural dysfunction from overt clinical disease.
Felton LM; Cunningham C; Rankine EL; Waters S; Boche D; Perry VH
Neurobiol Dis; 2005 Nov; 20(2):283-95. PubMed ID: 15886005
[TBL] [Abstract][Full Text] [Related]
56. Prion disease is accelerated in mice lacking stress-induced heat shock protein 70 (HSP70).
Mays CE; Armijo E; Morales R; Kramm C; Flores A; Tiwari A; Bian J; Telling GC; Pandita TK; Hunt CR; Soto C
J Biol Chem; 2019 Sep; 294(37):13619-13628. PubMed ID: 31320473
[TBL] [Abstract][Full Text] [Related]
57. Absence of detectable IL-1beta production in murine prion disease: a model of chronic neurodegeneration.
Walsh DT; Betmouni S; Perry VH
J Neuropathol Exp Neurol; 2001 Feb; 60(2):173-82. PubMed ID: 11273005
[TBL] [Abstract][Full Text] [Related]
58. Cell adhesion molecule CD44 is dispensable for reactive astrocyte activation during prion disease.
Bradford BM; Walmsley-Rowe L; Reynolds J; Verity N; Mabbott NA
Sci Rep; 2024 Jun; 14(1):13749. PubMed ID: 38877012
[TBL] [Abstract][Full Text] [Related]
59. Role of Erk1/2 activation in prion disease pathogenesis: absence of CCR1 leads to increased Erk1/2 activation and accelerated disease progression.
LaCasse RA; Striebel JF; Favara C; Kercher L; Chesebro B
J Neuroimmunol; 2008 May; 196(1-2):16-26. PubMed ID: 18396336
[TBL] [Abstract][Full Text] [Related]
60. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease.
Meier P; Genoud N; Prinz M; Maissen M; Rülicke T; Zurbriggen A; Raeber AJ; Aguzzi A
Cell; 2003 Apr; 113(1):49-60. PubMed ID: 12679034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
